Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth

Summary

• Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas.
• Recent study suggests Cushing's Syndrome is more prevalent than believed, leading to a significant expansion of its potential patient base.
• Corcept has developed Relacorilant as a far safer and more effective drug than its current drug Korlym for Cushing's which has just gone generic.
• Corcept broke the code defying Major Pharma for years and identified 1000 cortisol modulating compounds to address 17 diverse therapeutics areas with 10 currently in Phases 1, 2 & 3.
• Despite a patent challenge, Corcept's stock is potentially significantly undervalued, with the company poised for five to 10 years of strong double digit percentage growth in patient count, revenue and earnings.

Ca-ssis/iStock via Getty Images

CORT has generated a 28%/year compound return the last 10 years

INTRODUCTION

Corcept Therapeutics Is the Industry Leader in Cortisol Modulation, but is Relatively Unknown and Under-followed. After a Covid impacted Slowdown, Corcept Is on the Cusp

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CORT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article expresses my personal beliefs and opinions relating to the subject matter contained in the article. Other than payment from Seeking Alpha for the publication of this article, I have not been compensated by any entity, and all thoughts, opinions, conclusions and statements contained in this article are my own. Further, I have no affiliations or arrangements of any kind with any entity mentioned in this article. Finally, I have purchased shares of CORT for myself and for my clients in the past, and if the companies continue to perform as I expect, it is likely that I will purchase additional shares, both for myself and for my clients. This report is not, and should not be construed as a solicitation or offer to buy or sell any securities or related financial products. It has been prepared by me solely from publicly available information. The information contained herein is believed to be reliable but has not been independently verified. I make no guarantee, representation or warranty, and accept no responsibility or liability whatsoever as to the accuracy, completeness or appropriateness of such information or for any loss or damage arising from the use or further communication of this report or any part of it. Information contained herein may not be current due to, among other things, changes in the financial markets or economic environment. Opinions reflected in this report are subject to change without notice. This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. The report has been prepared without regard to the individual financial circumstances, needs or objectives of persons who receive it. The securities and investments related to the securities discussed in this report may not be suitable for all investors. Readers should independently evaluate particular investments and strategies, and seek the advice of a financial adviser before making any investment or entering into any transaction in relation to the securities mentioned in this report. I wish to thank my partner, Benjamin Bratt, for his advice and for constructing the financial models.